Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials.
暂无分享，去创建一个
M. Carrier | L. Muhlbaier | Peter K. Smith | E. Verrier | S. Shernan | J. Levy | P. Adams | T. Todaro | John C. Chen | Thomas G. Todaro | Peter K. Smith